This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Cognitive subdomain responses to galantamine in Alzheimer’s disease


Song, Jihye, Ahn, Inn Sook, Kang, Hyo Shin, Myung, Woojae, Lee, Yujin, Woo, Sook-young, Ku, Hyoung Mo, Hwang, Tae-Young, Carroll, Bernard J., Kim, Doh Kwan


The Journal Of Nervous And Mental Disease, Volume: 202, No.: 3, Pages.: 253-259

Year of Publication



We investigated the effects of galantamine on cognitive subdomains in Alzheimer’s disease (AD). Sixty-six patients with mild-to-moderate AD received open-label galantamine for 52 weeks. Cognitive function was measured using the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog-K). Response to galantamine was defined as “improvement or no deterioration” on the total scores of the ADAS-cog-K at 26 weeks. In the overall intent-to-treat sample, we found less cognitive decline during 26 and 52 weeks than the expected untreated course as predicted by Stern’s equation. The operationally defined response rate at 26 weeks was 66.7%. The responders differed significantly from the nonresponders only in the memory and language domains but not in the domains of praxis or frontal/executive function or in secondary outcome measures of neuropsychiatric symptoms and activities of daily living. The subdomain analysis revealed an effect of galantamine on preservation of memory that was not apparent in the overall analysis. Failure to achieve responder status by 26 weeks was associated with no further possibility of response. ;

Bibtex Citation

@article{Song_2014, doi = {10.1097/nmd.0000000000000107}, url = {}, year = 2014, month = {mar}, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {202}, number = {3}, pages = {253--259}, author = {Jihye Song and Inn Sook Ahn and Hyo Shin Kang and Woojae Myung and Yujin Lee and Sook-young Woo and Hyoung Mo Ku and Tae-Young Hwang and Bernard J. Carroll and Doh Kwan Kim}, title = {Cognitive Subdomain Responses to Galantamine in Alzheimer's Disease}, journal = {The Journal of Nervous and Mental Disease} }


activities of daily living, administration & dosage, aged, aged, 80 and over, alzheimer disease, cholinesterase inhibitors, cognition disorders, complications, drug effects, drug therapy, etiology, executive function, female, galantamine, humans, male, memory disorders, neuropsychological tests, pharmacology, severity of illness index, treatment outcome

Types of Dementia

Alzheimer’s Disease

Types of Study

Before and After Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime